CIR-0602K Demonstrates Synergistic Metabolic Benefit with Tirzepatide: New Data Presented at ObesityWeek 2025
PR Newswire —
GRAND RAPIDS, Mich., Nov. 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by insulin resistance and metabolic dysfunction, will be presenting new data today at ObesityWeek® 2025 from preclinical obesity...